# Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

> **NCT02303769** · PHASE3 · COMPLETED · sponsor: **GL Pharm Tech Corporation** · enrollment: 309 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Tamsulosin HCL 0.4mg
- **DRUG:** Tamsulosin HCL 0.2mg

## Key facts

- **NCT ID:** NCT02303769
- **Lead sponsor:** GL Pharm Tech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-05
- **Final completion:** 2015-10
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2016-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303769, "Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02303769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*